Origin Therapeutics is poising for public listing on the Canadian Securities Exchange (CSE).
Actively managed investment issuer, focused on making equity investments in psychedelics-related companies where legally permitted, Origin Therapeutics, has announced it has filed its preliminary long form prospectus with the securities regulatory authorities in the provinces of British Columbia, Ontario, and Alberta.
The prospectus was filed to enable Origin to become a reporting issuer under the applicable securities legislation in the qualifying jurisdictions.
Origin Therapeutics CEO, Alexander Somjen, commented: “Upon completion of Origin Therapeutics’ intended public listing, retail investors would gain access and be able to participate in the growth of portfolio of companies that may not otherwise be accessible to them.
“All our portfolio companies are carefully selected for their strong leadership teams and high growth potential to deliver the best potential upside for our investors.”
The listing of the Common Shares on the CSE will be subject to Origin fulfilling all of the listing requirements and conditions of the CSE, including prescribed distribution and financial requirements.
So far, Origin Therapeutics has completed investments in its first five portfolio companies, including Microdose Psychedelic Insights, Ocean Bio Ltd., Dimensions Health Centres Inc., Xpira Pharmaceuticals Inc., and Tripsitter Clinic Corp..
“We are continuously reviewing several opportunities in the growing psychedelic space, and are excited to announce this initial cohort of portfolio companies. Origin Therapeutics will work closely with these companies to support their growth while continuing to identify investments consistent with our values and poised to deliver the best returns possible for our portfolio,” added Somjen.
The company highlights that there is no assurance that Origin will successfully achieve the listing, as planned, and that no securities are being offered or sold pursuant to the Preliminary Prospectus.
